Go to Contents

SILLAJEN

ENG
Pipeline development status Targeting, Attacking, and Eradicating Cancers®

TOP
PIPELINE
Pipeline development status

Pipeline development status

파이프라인 개요, 연구 현황
Pipeline Indication Drug
Candidate Preclinical Phase1 Phase2 Phase3 Market 		SIT/IIT Sites Sponsor
PEXA-VEC + LIBTAYO® Renal Cell
Carcinoma
SIT KOR,USA,
AUS etc		 신라젠
BAL0891 Solid
Tumors
SIT USA 신라젠
SJ-600 Series Solid
Tumors
SIT 신라젠
JX-970 Solid
Tumors
SIT USA 신라젠
PEXA-VEC + YERVOY® Solid
Tumors
IIT FR Centre Leon Berard
PEXA-VEC (Neoadjuvant) Solid
Tumors
IIT UK University of Leeds
PEXA-VEC + IMFINZI + TREMELIMUMAB Colorectal
Cancer
IIT USA National Cancer Institute
PEXA-VEC + αPD-L1 antibody Melanoma
SIT CN Lee's Pharma
PEXA-VEC (Neoadjuvant) Prostate
cancer
IIT AUS Transgene
PEXA-VEC + BAVENCIO + CYCLOPHOSPHAMID Solid
Tumors
IIT FR 신라젠

* SIT : Sponsor Initiated Trials
* IIT : Investigator Initiated Trials

PEXA-VEC + LIBTAYO®

  • Renal Cell Carcinoma
  • SIT
  • KOR, USA, AUS
신라젠
+

BAL0891

  • Solid Tumors
  • SIT
  • USA
신라젠

SJ-600 Series

  • Solid Tumors
  • SIT
신라젠

JX-970

  • Solid Tumors
  • SIT
  • USA
신라젠

PEXA-VEC + YERVOY®

  • Solid Tumors
  • IIT
  • FR
Centre Leon Berard

PEXA-VEC (Neoadjuvant)

  • Solid Tumors
  • IIT
  • UK
University of Leeds

PEXA-VEC + IMFINZI + TREMELIMUMAB

  • Colorectal Cancer
  • IIT
  • USA
National cancer institute

PEXA-VEC + αPD-L1 antibody

  • Melanoma
  • SIT
  • CN
lee's pharm

PEXA-VEC (Neoadjuvant)

  • Prostate cancer
  • IIT
  • AUS
신라젠

PEXA-VEC + BAVENCIO + CYCLOPHOSPHAMIDE

  • Solid Tumors
  • IIT
  • FR
transgene

* SIT : Sponsor Initiated Trials
* IIT : Investigator Initiated Trials